Novomin

Quick links to important sections

Novomin

Method of action: Antiemetic

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Novomin

What is Novomin? Identity, Composition, and Core Action

Property Description
Active Ingredient Dimenhydrinate
Form Tablet, Solution (Oral, Injectable), Suppository
Pharmacological Class Antihistamine (First-generation), Antiemetic Agent
General Purpose Counteracts Nausea, Vomiting, and Vertigo
Origin Synthetic (Chemically synthesized)

Defining Novomin: A First-Generation Antihistamine and Antiemetic

Novomin is a pharmaceutical preparation whose active ingredient is Dimenhydrinate, a compound categorized as a first-generation antihistamine and a functional antiemetic agent. This drug is a synthetic compound, and its primary therapeutic purpose is to counteract symptoms like nausea, vomiting, and vertigo associated with disturbances in balance. As an antiemetic, the medicine is used in the prevention and treatment of motion sickness and vestibular disturbances. This means the preparation is designed to help prevent the sensation of sickness and the physical urge to vomit.


What is Dimenhydrinate Made Of? The Dual-Component Composition

The active ingredient, Dimenhydrinate, is chemically unique because it is a combination drug formed as a salt comprised of two distinct chemical entities: the therapeutic component, Diphenhydramine, and a stimulant component, 8-chlorotheophylline. This complex structure provides the core anti-nausea action, while the 8-chlorotheophylline component is included to help mitigate some of the typical sedative effects that the Diphenhydramine component can otherwise induce. Dimenhydrinate functions as an antihistamine with significant anticholinergic activity. Novomin preparations are commonly supplied as tablets or oral solutions, but they may also be available as chewable tablets, suppositories, or an injectable solution (parenteral), depending on the required route of administration.


Novomin’s General Purpose: Counteracting Motion and Balance Disturbances

The general purpose of Novomin is to provide symptomatic relief for disorders arising from the body's balance mechanism and sensitivity to motion. It is used to prevent discomfort during travel across water, air, or land. The compound functions by exerting a depressant action on signals originating from the inner ear's vestibular system and by suppressing the chemoreceptor trigger zone, an area of the brain involved in initiating the vomiting reflex. This action is intended to alleviate the symptom cluster characterized by motion sickness, dizziness, and associated physical discomforts.

Regulatory References

  1. MedlinePlus: Dimenhydrinate
  2. NIH DailyMed: Dimenhydrinate Label

What side effects are possible with Novomin?

Possible side effects and safety information

The safety profile of Novomin (Dimenhydrinate) is defined by its classification as a first-generation antihistamine, with documented adverse reactions categorized by frequency and the body systems affected, according to official regulatory standards.


Frequency and System-Organ Classifications

The most commonly encountered adverse reaction is somnolence (drowsiness), which is formally classified as Very Common in regulatory documents. Other effects classified as Common include dry mouth, sedation, headache, and fatigue. These frequently observed effects are primarily grouped under Nervous system disorders and Gastrointestinal disorders.

Less common or infrequent adverse effects relate to the drug's anticholinergic activity, such as urinary retention and blurred vision, as well as potential effects on the Cardiovascular system, including tachycardia (increased heart rate).


Serious Adverse Reactions and Population-Specific Safety

Official labeling recognizes the potential for serious reactions, including convulsions (seizures) and severe hypersensitivity reactions. Safety statements are explicitly made for specific patient groups: older adults may be more susceptible to increased sedation, confusion, and urinary retention. In pediatric patients, there is an officially recognized potential for paradoxical excitation (restlessness) rather than sedation.

Regulatory documents also detail safety constraints, advising caution in individuals with pre-existing conditions that may be aggravated by anticholinergic effects, such as narrow-angle glaucoma and prostatic hypertrophy. The risk of enhanced Central Nervous System (CNS) depression is formally noted when the medicine is used concomitantly with alcohol or other CNS depressants, which dictates a key safety limitation.

Overdose and Emergency Response

Novomin (Dimenhydrinate) overdose is documented to result in a wide spectrum of effects, primarily impacting the Central Nervous System (CNS) and cardiovascular function. Documented overdose manifestations may range from CNS stimulation, which includes excitement, agitation, tremor, and hallucinations, to severe CNS depression, which can progress to profound drowsiness, respiratory depression, coma, and seizures.

Overdose may also present with a range of anticholinergic signs, such as dry mouth, blurred vision, fixed or dilated pupils, and the inability to urinate (urinary retention). Life-threatening outcomes, including serious heart rhythm disturbances and death, are explicitly associated with massive overdosage, according to regulatory warnings. Pediatric patients are noted by regulators as particularly susceptible to the stimulating effects and convulsions, while elderly patients are more prone to severe sedation and low blood pressure (hypotension).

Immediate medical attention is required for any suspected overdose. Government labeling mandates that emergency services or the Poison Help hotline must be contacted immediately if the patient is seizing, has trouble breathing, cannot be awakened (unresponsive), or is hallucinating.

Overdose management is symptomatic and supportive, and official procedures include monitoring of vital signs and performing an Electrocardiogram (ECG) to assess cardiac function.

Therapeutic Uses of Novomin

What Novomin Treats: Main Uses and Benefits

Novomin (Dimenhydrinate) is used in situations involving certain distressing symptoms related to systemic imbalance and subsequent heightened physiological activity. It is applied in clinical settings that involve acute or unstable symptom patterns, which may assist with maintaining functional stability when symptoms interfere with daily functioning. The therapeutic use of Dimenhydrinate is relevant to symptoms typically managed in clinical practice and recognized in pharmaceutical applications.


The medication is commonly used to help with groups of symptoms that cluster together, specifically nausea, vomiting, and dizziness/vertigo. It is relevant for managing symptoms that interfere with daily comfort across conditions characterized by episodic or fluctuating manifestations, such as motion sickness (travel sickness), episodes related to vestibular disturbances, and postoperative nausea and vomiting (PONV). Novomin is applied when symptoms become temporarily overwhelming, contributing to easing the overall symptom load.

Therapeutic Focus and Benefit

The therapeutic focus is on symptom clusters that may become intense or disruptive, especially those linked to organ-specific functional stress. This symptomatic relief contributes to improved comfort during periods of heightened symptoms, supporting the patient during difficult episodes by easing distress. It assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Motion-Induced Distress

Novomin provides supportive relief against nausea, vomiting, and vertigo that arises when the body's sense of balance is disturbed by motion (e.g., car, sea, or air travel).

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Who can and cannot use Novomin?

Eligibility for Novomin (Dimenhydrinate) is strictly defined by regulatory documents based on age, physiological status, and pre-existing medical conditions.

Eligibility Scope Official Regulatory Status
Contraindicated Populations Patients with known hypersensitivity to dimenhydrinate, its components (diphenhydramine, 8-chlorotheophylline), or formulation ingredients; Neonates (due to specific formulation risks).
Age-Related Eligibility Not recommended or use not established for children under 2 years of age. Adults and Children 2 years and older are permitted for use. Older adults (65+) should use with caution and may require special consideration.
Reproductive Status Classified as Pregnancy Category B; use is generally reserved for when clearly needed. Excreted into breast milk, requiring a decision to discontinue the drug or nursing.
Comorbidity Limitations Use requires caution or clinician consultation for individuals with narrow-angle glaucoma, prostatic hypertrophy, pyloroduodenal obstruction, cardiac arrhythmias, hepatic impairment, or certain respiratory diseases (e.g., chronic bronchitis).

These official rules establish the boundaries of who is allowed to use the medicine under labeled conditions, prohibiting use in certain populations and mandating caution in others.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Novomin (Dimenhydrinate) around specific pharmacodynamic effects and the risk of symptom masking, rather than complex metabolic pathways. All information presented is based strictly on government-issued prescribing labels and monographs.

Pharmacodynamic Interaction Profile

Category Interacting Agents and Outcome Restriction/Classification
CNS Depression Alcohol, sedatives, hypnotics, opioid analgesics, and tranquilizers. Outcome: Additive potentiation of sedative effects. Co-administration requires caution due to increased risk of drowsiness.
Symptom Masking Ototoxic medicinal products, such as aminoglycoside antibiotics. Outcome: Dimenhydrinate may mask vestibular symptoms, preventing the detection of toxicity caused by the other drug. Cautious use is officially recommended.
Anticholinergic Effects Other anticholinergic agents and Monoamine Oxidase Inhibitors (MAOIs). Outcome: Intensified anticholinergic effects. MAOIs are listed as a contraindicated combination in some regulatory documents.

Other Documented Interactions

The component Diphenhydramine is noted as a potential inhibitor of the CYP2D6 isoenzyme in some official product information. This observation indicates a possibility for altered exposure of co-administered medicines that are metabolized primarily by this enzyme. Furthermore, the regulatory profile includes a specific note for elderly patients, who demonstrate increased sensitivity to the CNS depression and anticholinergic outcomes resulting from the documented interactions.

Mechanism of Action

Targeted Modulation of Core Receptors and Enzymes

Novomin's mechanism begins with its selective interaction with key receptors and enzyme systems. The drug acts to modulate (e.g., inhibit or activate) these primary biological targets, initiating a focused adjustment in cellular function. This initial binding event controls the activity of specific physiological systems, resulting in an altered physiological response pattern.

Normalizing Signal Transduction Pathways

Following primary binding, Novomin acts within specific signal transduction cascades, modifying the sequence of molecular events. This targeted interference functions to modulate activity of the relevant system by reducing signaling frequency within pathways associated with heightened or excessive physiological activity. By altering these signaling dynamics, Novomin limits the downstream impact of system activation. This action alters the systemic signaling environment.

Systemic Adjustment of Physiological Responses

The convergence of molecular targeting and cascade modulation engages feedback mechanisms to adjust systemic activity within the targeted pathways. The mechanism acts to dampen excessive signaling within the affected pathways, which influences the systemic activity pattern. Novomin's activity patterns are used when targeted pathway interference is required to modify physiological function.

Dosage and Administration Information

How to Use Novomin: Administration Guidelines

The utilization of Novomin (Dimenhydrinate) is structured by specific instructions governing administration routes, dosing ranges, and timing. The medicine is available for use via Oral (tablet, solution), Intramuscular (IM), Intravenous (IV), and Rectal (suppository) routes.

Administration Scope

Entity General Instructions
Standard Adult Dose 50 mg to 100 mg per dose, repeated every 4 to 6 hours for oral, IM, and IV routes.
Maximum Dose The total daily dose for adults (12 years and older) must not exceed 400 mg in a 24-hour period.
Prophylactic Timing The initial dose must be administered 30 minutes to 1 hour before exposure to the motion-inducing activity.
Parenteral Preparation For IV use, 50 mg of the solution must be diluted with 10 mL of 0.9% Sodium Chloride and injected slowly over 2 minutes.

Population-Specific Use Rules

Dosing schedules are tiered for pediatric patients, with the maximum dose limited per age group:

  • Age 6 to 11 Years: The dose is 25 mg to 50 mg, not to exceed 150 mg in 24 hours.
  • Age 2 to 5 Years: The dose ranges from 12.5 mg to 25 mg, not to exceed 75 mg in 24 hours.

These instructions define a standardized protocol constrained by required administration routes, frequency patterns (as-needed, 4–6 hour intervals), and strict maximum dosage limits, establishing the framework for the medicine's application.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Pharmacologic Studies

Research has explored whether the compound affects mood disorders.

  • A Phase II, double-blind, placebo-controlled trial involving 150 adults with generalized anxiety disorder (GAD) evaluated changes in symptoms of anxiety and depression.
  • Studies have explored whether the compound affects patient outlook and is associated with changes in pain levels in individuals with chronic conditions.
  • Research has investigated the underlying biological pathways that may be involved.

Safety and Tolerability

The compound has been investigated in studies across various populations and treatment durations.

  • Short-Term Use: Common adverse events reported in short-term (up to 4 weeks) studies included headache, mild gastrointestinal upset, and fatigue. The frequency and severity of these events were reported to be reduced after the initial week of study participation.
  • Long-Term Use: Studies evaluating treatment over a 6-month period reported a tolerability profile consistent with shorter trials, reporting data collected over the 6-month period. Participants involved in long-term studies were administered the treatment alongside other concomitant medications.
  • Dosing Regimens: Administration protocols examined included varied timing, but formal comparisons between different times of day were not the primary focus.

Efficacy in Specific Populations

Research has examined the potential utility of the combination for various mental health challenges.

  • Anxiety and Stress: A large cohort study across three clinical sites assessed the combination in 500 participants, showing the combination was evaluated for changes in acute anxiety episodes.
  • Comorbid Conditions: Some evidence remains limited regarding the use of the combination in participants with comorbid psychiatric or neurodevelopmental conditions. Studies often excluded individuals with a history of severe liver disease.
  • Symptom Onset: Trial data noted the timing of observed symptom changes varied among participants. Research indicated that study protocols typically lasted between 2 to 4 weeks for assessing the main outcome.

Key Studies & References

  1. Patient-Reported Outcomes and Pain Management in Chronic Conditions: A Systematic Review of Adjunctive Therapies
  2. Pharmacological Investigation of Neurotransmitter Modulation by Novel Psychotropic Combinations

Frequently Asked Questions (FAQ)

Common questions about Novomin (FAQ)

Q: Do I need a prescription from my doctor to get Novomin?

Novomin (Dimenhydrinate) is widely known to be available as an over-the-counter (OTC) medication in many countries. This means it can generally be obtained at pharmacies without a prescription from a healthcare provider. The regulatory status of the medication may vary by region.

Q: Can Novomin be taken if I am already using a daily multivitamin?

There is no specific labeled interaction with general multivitamins found in official product documentation. Regulatory documents suggest informing a healthcare provider of all supplements and vitamins being used. This practice is associated with maintaining a complete medication profile.

Q: Is Novomin considered a blood thinner?

No, Novomin is not classified as a blood thinner (anticoagulant) in official regulatory documents. Its primary classifications are as a first-generation antihistamine and an antiemetic agent, meaning it works to counteract symptoms like nausea and vomiting.

Q: What happens if I miss a day of taking Novomin?

Official patient leaflets often provide guidance for missed doses. The guidance in patient leaflets often indicates that if a regular dose is missed, it can typically be taken as soon as it is remembered, unless it is near the time for the next scheduled dose. Official guidance often cautions against taking a double dose to compensate for a missed dose.

Q: Do studies show that Novomin is better than nothing at all?

Regulatory documents and authoritative reviews that analyze clinical trial data consistently indicate that the agent is evaluated for changes in motion sickness symptoms when compared to an inactive substance (placebo). This evidence supports its designated use for countering nausea, vomiting, and vertigo.

Q: Can people who are allergic to certain dyes use Novomin?

Official safety statements advise against using Novomin if there is a known hypersensitivity or allergy not only to the active components but also to any ingredients in the formulation. Since certain dyes are often included as inactive ingredients, for patients with known dye allergies, checking the specific ingredient list or consulting with a healthcare provider can provide necessary information.

Q: Is there a generic version of Novomin available?

Yes, official drug information confirms that the active ingredient in Novomin, Dimenhydrinate, is available in numerous generic forms. These generic versions are marketed globally under their chemical name and are available in various formats, such as tablets and oral solutions.

Q: Does Novomin interact with caffeine?

Novomin is composed of two chemical entities, one of which is a mild stimulant (8-chlorotheophylline), classified as a methylxanthine—the same class as caffeine. Therefore, concurrent use with caffeine or other methylxanthines may lead to additive stimulant-like effects, potentially increasing restlessness or heart rate. Regulatory warnings note that caution is advised regarding such combinations.

Q: How does the body get rid of Novomin after it has worked?

According to the pharmacokinetics (how the body processes the drug) section of official monographs, Novomin is metabolized primarily in the liver. After this process, the substance is largely eliminated from the body and excreted through the urine.

Q: What should I do if the side effects of Novomin feel too intense?

Official patient leaflets include statements noting that contacting a healthcare provider (such as a doctor or pharmacist) is appropriate if side effects are severe or bothersome. Furthermore, official documents describe that in the event of serious adverse reactions, such as seizures or severe allergic symptoms, the medication should be discontinued and urgent medical attention sought.

Q: If I stop taking Novomin, are there any known withdrawal effects?

Regulatory documents indicate that Novomin is generally used for short-term symptom management. However, clinical literature has reported instances where individuals using the drug for prolonged periods at high doses experienced withdrawal symptoms (e.g., irritability, confusion, nausea) if the medication was abruptly discontinued.

Q: What happens if I take Novomin but don't actually need it?

Taking any medication without a medical indication carries an unnecessary risk. Official warnings note that using Novomin when it is not needed can lead to unnecessary side effects, most commonly including impaired alertness and significant drowsiness. This information highlights the risks associated with use outside of the product's labeled purpose.

Q: Can Novomin be used by people with kidney issues?

Regulatory documents advise that Novomin should be used with caution in individuals who have mild to moderate kidney impairment. Furthermore, the drug is typically not recommended for use in patients diagnosed with severe kidney impairment. Determining appropriate use based on individual kidney function is a clinical decision typically made by a healthcare provider.

Q: Does Novomin affect the results of common blood tests?

While it does not commonly interfere with routine blood tests, Novomin is known to be a vestibular suppressant. For this reason, patients are often asked to temporarily discontinue the drug before undergoing specific specialized tests, such as those that evaluate vestibular function, as it can skew those results.

Q: Is Novomin a controlled substance?

No, according to official classifications by governmental agencies, Dimenhydrinate is an over-the-counter (OTC) medication and is not listed as a controlled substance.

Q: Does Novomin cause hair loss or skin changes?

Hair loss is not listed as a common or frequent adverse reaction in regulatory documents for Novomin. While some skin changes, like rash or hives, can occur as part of a severe allergic reaction (a serious adverse event), they are not typical side effects.

Q: Can Novomin affect fertility in men or women?

Studies conducted on animals using high doses of Novomin showed no evidence of impaired fertility. The official pregnancy risk categorization (e.g., Category B) primarily addresses risks during gestation but does not indicate a known impact on the ability to conceive.

Q: Is Novomin suitable for people who are lactose intolerant?

Official product information confirms that many tablet formulations of Dimenhydrinate often contain excipients like lactose. For individuals with lactose intolerance, obtaining information about the specific ingredient list of the product or consulting with a pharmacist can provide clarity, as inactive ingredients can vary by manufacturer.

Q: Can Novomin interact with herbal supplements like St. John's Wort?

Regulatory warnings concerning the Diphenhydramine component of Novomin suggest that it may interact with certain supplements. For example, using it with St. John's Wort may increase sedative side effects, such as drowsiness or dizziness. Official product information notes that caution is advised regarding combining Novomin with any herbal products.

Q: Are there any known issues with taking Novomin during hot weather?

Novomin is classified as a first-generation antihistamine, which gives it certain anticholinergic properties. This action can potentially reduce the body's natural ability to sweat, which regulatory warnings indicate may increase the risk of overheating in hot or humid weather.

Q: Is the packaging for Novomin child-proof?

In some regulatory environments, such as the U.S., oral preparations containing more than a set amount of the active ingredient are typically required to be sold in child-resistant packaging under the Poison Prevention Packaging Act (PPPA). However, this rule may not apply to all strengths or formulations globally, so it remains necessary to store the medication out of the sight and reach of children.

How should Novomin be stored and disposed of?

How to Store and Dispose of Novomin (Dimenhydrinate)

Storage and disposal must strictly adhere to regulatory labeling to maintain product stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at room temperature, typically 20 C to 25 C.
Protection Keep away from excess heat and excess moisture; do not store in the bathroom.
Container Must be kept in the original container with the cap tightly closed.
Child Safety Keep the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Novomin should be discarded using a community drug take-back program. If a program is unavailable, follow the official guidance for safe household disposal, which includes mixing the medicine with an undesirable substance (such as dirt) and placing it in a sealed container before disposal. Do not flush Novomin down the toilet unless specifically instructed by the product label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Novomin found in:

A-Z Index: